Theradiag Reports Revenue of €6.3 Million for the First Half of 2022, Up 14.3%

• Solid growth of 9.3% for Theranostics
• Strong growth of 19.3% in IVD (In Vitro Diagnostics) activity
• Cash position of €6.0 million on June 30, 2022, in line with the budget

CROISSY-BEAUBOURG, France--(BUSINESS WIRE)--Regulatory News:

THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and Theranostics, today announced its half-year revenue and cash position on June 30, 2022, data that is currently being audited.

H1 2022 revenue of €6.3 million

Over the six months to June 30, 2022, Theradiag generated revenue of €6.3 million, compared with €5.5 million in the first half of 2021, giving growth of 14.3%.

Theranostics activity recorded another semester of solid growth, with revenue increasing by 9.3% to more than €3.0 million on June 30, 2022. This activity keeps on growing thanks to dynamic sales of the automated i-Track¹⁰ driven by an expanding range of i-Tracker^® tests adapted to this analyzer that thus allows the development of individualized therapeutic monitoring of even more biotherapies.

In France, Theranostics saw a solid level of activity with sales increasing by 10.5% to over €1 million. Abroad, Theranostics activity also generated satisfactory sales of approximately €2.0 million, up 8.7% compared with the first half of 2021. Moreover, the Company is in a period of reflection in order to optimize its commercial activities on the North American market.

IVD (In Vitro Diagnostics) activity recorded strong sales growth of 19.3% to over €3.2 million on June 30, 2022. This activity achieved a particularly noteworthy performance in France, where sales jumped by 29.3% to €2.1 million. These exceptional performances are the result of non-recurrent commercial opportunities. Indeed, during the first half of this year, Theradiag recorded some opportunistic sales of diagnostic instruments, notably to the veterinary sector, and logged sales of genetic tests that were temporarily increased before the closure and resumption of this distribution line.

Cash position

Theradiag had a net cash position of €6.0 million on June 30, 2022, versus €7.1 million on December 31, 2021. This level is in line with the Company’s roadmap outlined at the time of the rights issue carried out in October 2021.

Bertrand de Castelnau, Theradiag’s CEO, commented: “Theradiag is continuing to record solid commercial performances in the first half of 2022. We were able to maintain our customary growth in Theranostics and make the most of market opportunities in in vitro diagnostics. Along with this good sales dynamic, strategic and structural milestones were achieved by the Company in terms of R&D, such as the launch of ez-Track¹ that is accelerating our differentiation in biotherapy monitoring and strengthening our leadership position on this market. Moreover, Theradiag has taken the implementation of IVDR^* onboard and is focusing its attention on the next measures imposed by this new regulation. In the second half of 2022, we will strive to continue implementing our strategic plan that will allow us to improve all our financial indicators.”

Pierre Morgon, Chairman of Theradiag’s Board of Directors, added: “Theradiag keeps on developing its Theranostics activity, which is the cornerstone of its growth strategy, and will remain agile by seizing any opportunities that arise on the IVD market. This strategy is enabling Theradiag to establish its leadership position on its key markets, which have excellent prospects.”

Reminder of the main H1 2022 highlights

• January 2022: Signing of a distribution agreement with BIOSYNEX of their AMPLIQUICK SARS-CoV-2 PCR test
• May 2022: Launch of two new i-Tracker^® kits: i-Tracker^® Certolizumab and i-Tracker^® Anti-Certolizumab
• May 2022: Launch of ez-Track¹, a Point-of-Care Testing solution for therapeutic drug monitoring
• June 2022: Partnership with Quotient Limited to advance autoimmune disease diagnostics

Next financial press release:

- H1 2022 results, on Monday September 19, 2022, before market

About Theradiag

Theradiag is the market leader in biotherapy monitoring. Capitalizing on its expertise in the diagnostics market, the Company has been developing, manufacturing and marketing innovative in vitro diagnostic (IVD) tests for over 30 years.

Theradiag pioneered “theranostics” testing (combining therapy with diagnosis), which measures the efficacy of biotherapy in the treatment of chronic inflammatory diseases. Going beyond mere diagnosis, Theranostics aims to help clinicians set up “customized treatment” for each patient. This method favors the individualization of treatment, evaluation of its efficacy and the prevention of drug resistance. In response to this challenge, Theradiag develops and markets the CE-marked TRACKER^® range, a comprehensive solution of inestimable medical value.

The Company is based in Marne-la-Vallée, near Paris, has operations in over 70 countries and employs over 60 people. In 2021, the Company posted revenue of €11.1 million. The Theradiag share is listed on Euronext Growth Paris (ISIN: FR0004197747) and is eligible for the French PEA-PME personal equity plan. For more information about Theradiag, please visit our website: https://www.theradiag.com/

____________________________
^* New EU regulation covering in vitro medical devices justifying the granting or renewal of CE Marking since May 26, 2022.

Theradiag
Bertrand de Castelnau
CEO/Managing Director
Tel.: +33 (0)1 64 62 10 12
contact@theradiag.com

NewCap
Financial Communications & Investor Relations
Pierre Laurent / Quentin Massé
Tel.: +33 (0)1 44 71 94 94
theradiag@newcap.eu

NewCap
Media Relations
Nicolas Mérigeau
Tel.: +33 (0)1 44 71 94 98
nmerigeau@newcap.fr